<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623633</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001612</org_study_id>
    <nct_id>NCT03623633</nct_id>
  </id_info>
  <brief_title>Comparative Antiresorptive Efficacy Discontinuation of Denosumab</brief_title>
  <official_title>Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of Denosumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis remains a significant healthcare burden for the United States. Current
      FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates,
      denosumab, and raloxifene.

      Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator
      of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity
      but bone turnover rapidly normalizes and bone turnover marker levels can rebound above
      baseline levels after the drug is discontinued.

      The proposed study will help us determine the relative efficacy of two oral antiresorptive
      medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate
      and raloxifene) in preventing the rebound increase in bone turnover that occurs after
      denosumab discontinuation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum c-telopeptide (CTX)</measure>
    <time_frame>18 months</time_frame>
    <description>Change in serum CTX between month 12 and month 18</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab and Raloxifene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>denosumab and raloxifene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab and Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>denosumab and alendronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>denosumab 60 milligrams subcutaneously every 6 months</description>
    <arm_group_label>Denosumab and Alendronate</arm_group_label>
    <arm_group_label>Denosumab and Raloxifene</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate</intervention_name>
    <description>alendronate 70 milligrams weekly</description>
    <arm_group_label>Denosumab and Alendronate</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raloxifene</intervention_name>
    <description>raloxifene 60 milligrams daily</description>
    <arm_group_label>Denosumab and Raloxifene</arm_group_label>
    <other_name>Evista</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women aged 45+

          -  postmenopausal

          -  osteoporotic with high risk of fracture as per National Osteoporosis Foundation
             guidelines

        Exclusion Criteria:

          -  no significant previous use of bone health modifying treatments

          -  hip fracture within one year of enrollment

          -  known congenital or acquired bone disease other than osteoporosis

          -  significant renal disease, liver disease, cardiopulmonary disease, or psychiatric
             disease

          -  abnormal calcium or parathyroid hormone level

          -  serum vitamin D &lt;20 ng/dL

          -  anemia (hematocrit &lt;32%)

          -  history of malignancy (except non-melanoma skin carcinoma)

          -  excessive alcohol use or substance abuse

          -  extensive dental work involving extraction or dental implant within the past 6 months
             or in the upcoming 12 months

          -  known contraindications to denosumab, alendronate, or raloxifene
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie David, BA</last_name>
    <phone>6177266129</phone>
    <email>ndavid2@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Sassana</last_name>
      <phone>617-724-2035</phone>
      <email>gsassana@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>February 15, 2019</last_update_submitted>
  <last_update_submitted_qc>February 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joy Tsai</investigator_full_name>
    <investigator_title>Instructor, Harvard Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

